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Determination of 
dehydroepiandrosterone and its 
biologically active oxygenated 
metabolites in human plasma 
evinces a hormonal imbalance 
during HIV-TB coinfection
María Belén Vecchione  1,2, Javier Eiras2, Guadalupe Verónica Suarez1, Matías Tomás Angerami1, 
Cecilia Marquez3, Omar Sued4, Graciela Ben5, Héctor Miguel Pérez5, Diego Gonzalez6,  
Patricia Maidana6, Viviana Mesch6, María Florencia Quiroga1 & Andrea Claudia Bruttomesso2
An estimated one third of the world’s population is affected by latent tuberculosis (TB), which once 
active represents a leading cause of death among infectious diseases. Human immunodeficiency 
virus (HIV) infection is a main predisposing factor to TB reactivation. Individuals HIV-TB co-infected 
develop a chronic state of inflammation associated with hypothalamic-pituitary-adrenal (HPA) axis 
dysregulation. This results in a hormonal imbalance, disturbing the physiological levels of cortisol 
and dehydroepiandrosterone (DHEA). DHEA and its oxygenated metabolites androstenediol (AED), 
androstenetriol (AET) and 7-oxo-DHEA are immunomodulatory compounds that may regulate 
physiopathology in HIV-TB co-infection. In order to study possible changes in plasma levels of these 
hormones, we developed an approach based on high performance liquid chromatography-tandem 
mass spectrometry (HPLC-MS/MS). To our knowledge, this represents the first report of their 
simultaneous measurement in HIV-TB individuals and the comparison with healthy donors, obtaining 
statistically higher plasma levels of DHEA, AET and 7-oxo-DHEA in patients. Moreover, we found that 
concentrations of 7-oxo-DHEA positively correlated with absolute CD4+ T cell counts, nadir CD4+ T 
cell values and with individuals who presented TB restricted to the lungs. This research contributes to 
understanding the role of these hormones in HIV-TB and emphasizes the importance of deepening their 
study in this context.
Tuberculosis (TB), a disease caused by the intracellular pathogen Mycobacterium tuberculosis (Mtb), is one of 
the ten leading causes of death worldwide, outweighing the number of demises attributed to human immunode-
ficiency virus (HIV)/AIDS. People infected with Mtb have a lifetime risk of progression to active TB of around 
10%, while individuals with a compromised immune system, such as in the case of HIV infection, are 17–22 times 
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more likely to develop the disease1. Around 14 million people are estimated to be co-infected with TB and HIV, 
together emerging as the leading infectious diseases in resource-limited countries2,3.
People co-infected with HIV-TB present chronically elevated pro-inflammatory cytokines which lead to 
hypothalamic-pituitary-adrenal (HPA) axis dysregulation4,5. Several cytokines can cross the blood-brain barrier 
and access the central nervous system, modulating hormone secretion6,7. These changes have been thoroughly 
studied in HIV, where HPA disorders may cause subclinical adrenal insufficiency leading to increased morbid-
ity and mortality8,9. Furthermore, many of the anti-retroviral drugs can contribute to HPA axis dysfunction8. 
Regarding Mtb-infected individuals, it was reported that patients exhibit altered plasma levels of cortisol, pro-
lactin, growth hormone, thyroid hormone, testosterone and dehydroepiandrosterone (DHEA)10. Together, the 
endocrine disturbances found in TB patients are related with worsened clinical status and unfavorable disease 
outcome11. Despite these data, reports about HPA imbalance during HIV-TB co-infection are very scarce. In 
HIV-TB individuals, an increased cortisol/DHEA ratio might lead to infection progression by inducing a shift 
from Th1 to Th2 immunologic responses12. Although the cross-talk between the immune and endocrine systems 
is responsible for an effective immune response against infectious agents13, the relevance of immune-endocrine 
interactions has not been fully elucidated yet.
DHEA is a hormone secreted mainly by the adrenal cortex, but also by the gastrointestinal tract, gonads, and 
brain. It serves several functions in the human body, which are classically associated with age-related changes 
such as metabolism alterations, cardiovascular disease, fertility and neuronal function14–16. However, it is now 
clear that DHEA is a regulator of immune functions, as it modulates the production of inflammatory cytokines, 
increases resistance to infections, exhibits antiviral activity and counteracts the immune-suppressive effects of 
glucocorticoids17–21. In previous studies, we demonstrated that DHEA modulates the immune response against 
Mtb, enhancing the cytotoxic Th1 and CD8+ T cell responses and negatively regulating the expression of tran-
scription factor FoxP3. In line with this, we observed that DHEA enhanced Mtb-specific Th1 responses from 
human dendritic cells in vitro12,22,23.
The pleiotropic effects of DHEA might be explained through its direct interaction with specific receptors and/
or its transformation into multiple metabolites24. On this issue, previous studies have reported that androsten-
ediol (AED) and androstenetriol (AET) upregulate host immunity, conferring protection against bacterial and 
viral infections in a mouse model. Moreover, AET treatment increases CD4+/CD8+ T lymphocyte ratio after 
irradiation and the levels of IL-2, IL-3, and IFN-γ, counteracting hydrocortisone immune suppression17,25–28. 
Additionally, 7-oxo-dehydroepiandrosterone (7-oxo-DHEA) has been reported as a thermogenic and neuro-
protective compound29,30, although its effects on the immune system have not been studied in depth. As this 
compound is not a precursor of biologically active androgens or estrogens, it is considered that it could substitute 
DHEA in replacement therapies31–33.
In order to study adrenal imbalance during HIV-TB co-infection, we developed a specific approach based 
on HPLC–MS/MS technology for simultaneous determination of DHEA, AED, AET and 7-oxo-DHEA levels in 
human plasma samples. This involved the use of an internal standard (IS) and a sensitive measurement without 
sample derivatization. Furthermore, we compared the results from our approach with a validated radioimmu-
noassay. Remarkably, the results obtained in this work revealed biological relevance, as we found statistically 
significant differences between groups when comparing the levels of DHEA, AET and 7-oxo-DHEA in a cohort of 
healthy donors (HD) with those found in HIV-TB co-infected patients. Moreover, we observed that 7-oxo-DHEA 
levels were related with clinical parameters associated with disease outcome.
Results
Among the main findings of this research: (1) The HPLC-MS/MS-based approach described here proved a sen-
sitive and specific methodology for measuring the steroids under study; (2) The use of an IS prevented interfer-
ences in extraction caused by differences in matrix complexities between HIV-TB and HD; (3) Notably, HIV-TB 
patients exhibited higher plasma levels of DHEA, AET and 7-oxo-DHEA compared with HD; 4) 7-oxo-DHEA 
levels were positively related with absolute CD4+ T cell counts, CD4+ T cell nadir values and the development 
of pulmonar instead of extrapulmonar TB.
HPLC-MS/MS approach for detection of steroid hormones: performance and validation 
results. We selected liquid chromatography-electrospray ionization tandem mass spectrometry as a tool to 
determine DHEA, AED, AET and 7-oxo-DHEA (Fig. 1) in human plasma samples. We used the method of mul-
tiple reaction monitoring (MRM) as a highly sensitive and selective technique for the quantitation of analytes in 
a complex biological matrix. In Table 1, we summarize the precursor and fragment ions, the optimized collision 
energy values and the retention times obtained in both the reference laboratory and the secondary laboratory. We 
evaluated the specificity of the method by comparing the chromatograms obtained from the analytes in a solution 
of MeOH with an extracted plasma sample, both fortified with standards and IS. Supplementary Fig. S1 depicts 
good chromatographic quality without significant interferences, giving a measurable response at the correspond-
ing retention times of the ions monitored. Therefore, it can be concluded that the approach developed here was 
specific for the compounds studied and did not result in artifacts or interfering peaks.
Matrix effects can cause disturbances in the slope of a calibration curve34. Therefore, we evaluated possible 
interferences by comparing the results from both solvent-treated and fortified pooled plasma calibration curves, 
with results showing no statistically significant differences between both curve slopes. Also, we calculated matrix 
effect (ME) by assessing the MS/MS response of analytes into a MeOH solution and a pooled plasma extract, 
obtaining values near 100% when relative recoveries were evaluated. These data indicate that the responses in 
both solutions were similar and that possible matrix effects during the process were compensated by the use of 
the IS added before extraction (Table 2). Thus, we decided to use external calibration for the validation analysis 
and analyte assessment in plasma samples. Finally, in order to demonstrate a proportional relationship between 
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the area ratios versus analyte concentration, we determined the linearity of the assay and observed high linear 
responses along the calibration range (3–3000 ng/ml, R2 > 0.994).
The limit of detection (LOD) is defined as the lowest analyte concentration that can be detected and distin-
guished from the noise level but not necessarily quantified, while the limit of quantitation (LOQ) represents the 
lowest concentration of analyte that can be determined quantitatively with an acceptable level of precision34. We 
Figure 1. Chemical structure of the analytes studied. The hormones dehydroepiandrosterone (DHEA), 
androstenediol (AED), androstenetriol (AET), 7-oxo-DHEA and the compound used as an internal standard 
(IS) are represented.
Analyte
Q1 Mass  
(Da)
Q3 Mass  
(Da)
Collision 
energy (V)
Retention 
Time A (min)
Retention 
Time B (min)
DHEA
271.1 253.1# 13
14.04 8.34
271.1 197.1 20
AED 273.1 255.1# 13 12.38 6.79
AET
289.2 271.4# 5
2.25 2.24
289.2 253.2 14
7-oxo-DHEA
303.2 285.2# 17
6.75 4.37
303.2 81.3 29
IS
369.1 309.3# 5
25.56 12.95
369.1 251.3 13
Table 1. Multiple reaction monitoring transitions and retention times. #Indicates ion quantified. Retention 
Time A corresponds to laboratory of reference (Thermo Fisher Scientific Inc. Ultimate 3000 RSLC Dionex 
HPLC) and Retention Time B to secondary laboratory (Agilent 1290 Infinity II LC with a ZORBAX Rapid 
Resolution High Definition).
Analyte ME (%) Linearity
LOD 
(ng/ml)
LOQ 
(ng/ml)
Accuracy 
(RE%)
Precision 
Intraday 
(CV%)
Precision 
Interday 
(CV%)
Relative R 
(%)
Absolute R 
(%)
PE 
(%)
DHEA 107 0.999 1 4
19.0
14.4
10.7
3.2
2.7
7.5
20.1
2.9
7.0
102 72 109
AED 96 0.997 3 8
−19.9
−5.1
1.9
11.9
2.6
11.0
16.1
5.8
7.6
105 70 101
AET 110 0.995 6 18
−12.2
−14.7
−4.4
17.3
6.0
6.1
15.9
8.0
4.8
99 75 109
7-oxo-DHEA 98 0.994 5 16
−19.7
12.9
14.9
7.6
6.8
10.1
20.1
5.9
9.9
109 73 106
Table 2. Validation results for the novel HPLC-MS/MS-based approach. Matrix effect (ME), linearity, limit of 
detection (LOD), limit of quantification (LOQ), accuracy, intra and interday precision, relative and absolute 
recoveries (R) and process efficiency (PE) for each steroid. Accuracy and precision were indicated for QC at 
LLOQ (top), LQC (middle) and HQC (bottom).
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achieved a LOD ranging between 1 and 6 ng/ml, while the LOQ varied from 4 to 18 ng/ml (Table 2). In a previous 
report using radioimmunoassay (RIA), we determined that DHEA plasma levels ranged from 0.5 to 10 ng/ml12. 
Taking these data and the LOQ obtained for DHEA into account, we concentrated the sample by taking the initial 
1000 μl of plasma in 100 μl of MeOH prior injection, therefore reaching the adequate concentration for the assay 
and demonstrating the accuracy and precision of analyte determination in our biological matrix. These param-
eters were calculated at 3 ng/ml as the lower limit of quantitation (LLOQ), 10 ng/ml as the lower quality control 
(LQC) and 3000 ng/ml as the higher QC concentrations from data obtained during 5-day validation (Table 2). In 
spite of the fact that the LOD for AET and 7-oxo-DHEA were slightly above the lowest point of the standard curve 
(3 ng/ml), this very low signal also exhibited precision and accuracy values that were in concordance with FDA 
guidelines35 (Table 2). Although further validation is required, we consider this methodology appropriate for the 
quantification of DHEA, AED, AET and 7-oxo-DHEA from human plasma samples and potentially suitable for 
clinical purposes.
Ethyl acetate (EtOAc) is a widely used solvent in industry owing to its affordability and low toxicity36. Due to 
the polarity of oxygenated metabolites, we chose this solvent to perform liquid-liquid extraction, which allowed 
us to satisfactorily recover the compounds from a complex matrix. To assess extraction efficiency, we deter-
mined the relative and absolute recoveries of the evaluated steroids, as described below (Table 2). Recovery of the 
analytes was analyzed by comparing the results from pooled plasma and from fortified pooled plasma after the 
extraction procedure. Results displayed adequate relative recovery values, while absolute recovery of the analytes 
declined to a similar extent for all compounds (Table 2)37. These data indicate that the chosen IS had a similar 
behavior to the analytes and that the matrix effect in the extractive process was similar for all the compounds. 
Also, we estimated process efficiency (PE) as the ratio of the response of an analyte spiked before extraction and 
the response of the same analyte in MeOH, which represents the combined effects of extraction recovery and 
matrix. We found that PE ranged from 101% to 109%, which indicates satisfactory results in the overall procedure 
(Table 2)37. Surprisingly, during the processing of samples, we observed discrepancies in the absolute recovery 
between HD and HIV-TB when quantifying IS in the context of a calibration curve in MeOH (Fig. 2). These sta-
tistically significant differences may indicate variations in matrix complexities, which we corrected through the 
use of an IS during sample processing.
Application of HPLC–MS/MS analysis to human plasma samples: biological relevance of 
the steroids studied. With the objective to study plasma levels of DHEA, AET, AED and 7-oxo-DHEA, 
HPLC-MS/MS was performed on samples from HD and a group of HIV-TB co-infected patients. Cohorts 
recruited in the current study did not present disparities in age or female/male distribution but there were 
significant differences in median CD4+ T cell counts, as expected (Table 3). We therefore report for the first 
time the simultaneous measurement of steroids DHEA, AET, AED and 7-oxo-DHEA in HIV-TB individuals 
by HPLC-MS/MS and their comparison with HD. Most interestingly, we observed statistically higher levels of 
DHEA, AET and 7-oxo-DHEA in HIV-TB, while no such result was found for AED (Fig. 3).
Afterwards, we aimed to compare the plasma steroid concentration determined by HPLC-MS/MS with 
that obtained by RIA and, alternatively, with the method described here performed in a different laboratory, 
employing different equipment and operator. First, we contrasted the results from HD samples with previous data 
obtained from an immunologically based method12 (Fig. 4a). Statistical analysis indicated that Spearman’s rank 
coefficient was over 0.8 (p < 0.005), which supports the idea that the degree of agreement between our approach 
Figure 2. Percent of IS recovered from plasma samples. Results are shown for samples from HD (white circles, 
n = 16) and HIV-TB patients (black circles,n = 17). Each symbol represents an individual subject. Horizontal 
lines represent mean values and error bars symbolize the standard error of the mean (SEM). Wilcoxon matched-
pairs signed rank test, **p < 0.01.
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and RIA could be clinically acceptable, even though more biological samples are needed to validate this result. 
Then, we tested interlaboratory reliability through a cross-validation assay. Plasma samples from disease-affected 
and non-affected individuals were included for comparison (Fig. 4b). We demonstrated a statistically significant 
correlation between the values from the laboratory of reference and the secondary laboratory, without differences 
among the data obtained (Mann-Whitney U test).
Finally, we contrasted the levels measured for each hormone with clinical data from the patients enrolled: 
sex, age, absolute CD4+ T and CD8+ T cell counts, CD4:CD8 cell ratio, CD4+ T cell nadir value, viral load, and 
localization of TB. Interestingly, we observed significant associations for 7-oxo-DHEA, not being able to find 
the same results when analyzing other steroids. Figure 5 shows the relationship between plasma concentration 
of 7-oxo-DHEA and the values of absolute CD4+ T cell count and the lowest ever CD4+ T lymphocyte count 
(CD4+ T cell nadir). Moreover, higher concentrations of 7-oxo-DHEA were associated with the development of 
pulmonar TB, while lower levels were related to extrapulmonar TB.
Discussion
In the current study, we propose a novel HPLC-MS/MS-based approach to simultaneously measure DHEA, AED, 
AET and 7-oxo-DHEA in human plasma. HPLC–MS/MS has been used in clinical laboratories during the last 
10–15 years, and steroids were among the first molecules to be quantified using this technology38. Triple quadru-
pole mass spectrometry has emerged as a tool for improving detection sensitivity and resolution, which results 
in a simultaneous qualitative and quantitative measurement. These features have added versatility to the analysis 
of several analytes in a small volume of sample38–40. Nonetheless, developing a protocol to quantitatively assess 
an analyte requires availability of standards to quantify each molecule and systematizing a procedure for efficient 
extraction recovery.
The measurement of analytes without derivatization is increasingly feasible due to the development of highly 
sensitive mass spectrometry equipment, achieving lower limits of quantitation41–43. The LOQs achieved in this 
work are comparable to those informed by other authors under similar conditions44. Better results have only 
been possible when a different ionization source was used or analytes were derivatizated44–46. Ideally, reaction of 
derivatization should be total, fast, and reproducible, without chemical artifact generation. Derivatization usually 
improves sensitivity, facilitating the ionization procedure, but these results are difficult to accomplish in complex 
matrices for polyhydroxylated compounds, as AED and AET, which can yield two or more products.
Regarding the transitions reported for each analyte, we detected only one fragment ion to quantify AED. In 
our assays, a wide range of collision energy values were tested in order to find fragment ions and to select the 
most abundant. As described before, several compounds show extremely high molecule stability, making it dif-
ficult to generate more than one fragment ion in the collision cell47,48. Furthermore, we resolved plasma sample 
components using an HPLC column before analytes were introduced into the mass spectrometer. Through this 
procedure, it was also possible to identify AED by its retention time.
Interfering peaks which co-elute with the analytes of interest can cause ionization suppression, thus impairing 
detection sensitivity49. We estimated this matrix effect (ME) by comparing analyte MS/MS response in a MeOH 
solution and a pooled plasma extract, obtaining similar behaviors, with results allowing the use of external cali-
bration for analyte measurement in plasma samples. Taking into account that we would need a large volume of 
plasma to build the calibration curve, this procedure would not be applicable in the clinic. In addition, as we 
showed in Fig. 2, the differences in the composition of the matrix of HD and coinfected patients would complicate 
the analysis. As a result, we decided to use MeOH to prepare the standard curve. Thus, the MeOH curve proved 
precise and accurate in quantifying the analytes in the matrix studied. Despite this, some samples were also ana-
lyzed using pooled plasma as matrix curve, also finding significant differences for DHEA, AET and 7-oxo-DHEA 
between HD and HIV-TB (data not shown).
To avoid matrix effects during sample preparation, we used an IS added at a concentration known prior to 
extraction50–52. If possible, the IS should be stable, with chromatographic and mass spectrometric ionization 
behavior comparable to that of the analytes. With the purpose of choosing an appropriate IS to be employed, 
preliminary experiments were carried out with the commonly used deuterium label, adding DHEA-16,16-d2 
before extraction. Our results indicate that a significant loss of the deuterium label occurred (data not shown), as 
previously reported by other authors53,54. Deuterium loss from the standards due to biological reactions or chem-
ical processes could compromise the accuracy of results, as it hinders reproducibility and may lead to erroneous 
concentration reports53,55. Even though the synthesis of stable 3α deuterium-labeled steroids has been reported56, 
obtaining these compounds is an extra step which increases the cost, time and complexity of the technique. 
Therefore, we decided to use a commercial IS with chemical and physical properties similar to those of the natural 
analytes and which is not present in the matrix studied, in order to relativize recovery to extraction efficiency.
When sensitivity is an issue, some reports propose the use of liquid-liquid extraction to enrich the sample 
with respect to the analyte and eliminate proteins and other hydrophilic metabolites57,58. A common problem in 
bioanalytical methods is that matrix effect may also alter recovery efficiency37. We calculated relative recovery 
HD (n = 16) HIV-TB (n = 17)
Median age in years (IQR) 30.0 (28.0–36.5) 34.5 (32.2–41.0)
Female/male distribution 6/10 4/13
Median CD4+ count (IQR) 607.0 (490.5–767.0) 117.2 (72.2–357.1)**
Median Viral Load (IQR) N/A 39,449 (845–81,475)
Table 3. Characteristics of the subjects enrolled. IQR: interquartile range. Mann-Whitney U test, **p < 0.01.
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and obtained satisfactory performances for all compounds, although we discovered variances between plasma 
samples from HIV-TB individuals and HD when absolute recovery was evaluated. This fact might be explained 
by differences in components of the matrix which interfere with the extraction process50. Chronic infections are 
known to involve an abnormal physiological concentration increase in protein and lipids. HIV-infected people 
develop multiple metabolic syndromes which are related to HIV-modulated and inflammation-related proteins, 
which enhance fatty acid synthesis, increase triglycerides levels, dysregulate lipid transport and alter cellular lipid 
metabolism59,60. Likewise, patients affected with TB present higher plasma levels of cytokines, C-reactive protein, 
matrix metalloproteinase-8 and alpha-1-antitrypsinin parallel with cortisol, estradiol, prolactin, growth hormone 
and thyroid hormone increases61–63. As in HIV-TB patients there is also an up-regulation of several proteins and 
Figure 3. HPLC-MS/MS-based approach application to human plasma samples. Plasma concentrations of 
DHEA, AED, AET and 7-oxo-DHEA measured by HPLC-MS/MS for HD (white circles) and HIV-TB patients 
(black circles). Each symbol represents an individual subject (n values are shown). Horizontal lines represent 
mean values and error bars symbolize SEM. Mann-Whitney U test,*p < 0.05, **p < 0.01.
Figure 4. Comparison tests performed with a fully validated method and interlaboratory approach. (a) 
Correlation curve of DHEA plasma levels determined by HPLC-MS/MS and RIA from HD samples. Number 
of pairs XY = 8. (b) Interlaboratory reliability through a cross-validation assay. DHEA, AED, AET and 7-oxo-
DHEA were determined both in the laboratory of reference and the secondary laboratory, and then the results 
obtained were compared by correlation analysis. Number of pairs XY = 10 (HD = 4, HIV-TB = 6). Solid lines 
represent linear regression curves and dotted lines symbolize 95% confidence intervals. Spearman’s rank 
correlation coefficient, p value and slope are indicated. *p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
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lipid synthesis64, we expected consequent changes in matrix composition which might explain the differences 
found in absolute extraction efficiency58. Given matrix complexity in the context of co-infection, we believe the 
use of an IS may be convenient to correct matrix interferences and to obtain accurate results.
Summarizing, our approach involves a liquid-liquid extraction, the use of a commercial steroid added before 
extraction as IS and no derivatization techniques. Taking into account the above and according to the current 
guidelines35, we consider this methodology sensitive and precise for simultaneous quantifications of the metabo-
lites in study. Future work will continue a thorough validation of this chromatographic method for the separation 
and quantitation of these and other significant steroids.
The assay developed allowed us to determine the concentrations of DHEA, AED, AET and 7-oxo-DHEA in 
human plasma samples. We used HD samples to evaluate the performance of the novel HPLC–MS/MS approach 
compared with RIA12, a validated radioimmunoassay. The results showed correspondence between both meth-
odologies, obtaining a statistically significant Spearman’s rank correlation coefficient of 0.8095. Additionally, we 
correlated the results from HD and HIV-TB samples determined in a reference laboratory with those obtained in 
a secondary laboratory, and found that regression curve slopes slightly differed among metabolites. Considering 
the results from this analysis (see Fig. 4), we conclude that the values in the secondary laboratory were similar to 
those acquired in the laboratory of reference. In contrast, the curve slopes of DHEA and AED were <1.0 (0.4540 
and 0.6090, respectively), indicating that the values from the secondary laboratory were lower.
It was previously observed that DHEA plasma levels measured by RIA are significantly diminished in HIV,TB 
and HIV-TB patients, compared to HD10,12,65–68. Moreover, antituberculous therapy seems to increase DHEA in 
plasma, restoring its concentration to the levels observed in healthy individuals65. Nevertheless, as shown before 
(Fig. 3), we observed that the HIV-TB cohort exhibited not only higher DHEA plasma levels, but also higher 
AET and 7-oxo-DHEA concentrations compared with HD. As discussed above, HIV-TB co-infection is a chronic 
inflammatory condition which dysregulates the production of cytokines and other compounds secreted by cells 
and tissues, as hormones or acute-phase proteins11,69. Therefore, we propose that the discrepancy between plasma 
DHEA concentration obtained by HPLC-MS/MS and RIA might be caused by differences in extraction efficiency 
due to matrix complexities, which can be solved with the use of an IS. As the radioimmunoassays used in clinical 
practice do not take advantage of including standards in their methodology, this generates a problem in sample 
preparation which cannot be solved.
Understanding the complex changes taking place during HIV-TB co-infection might lead to the identification 
of prognostic markers and the development of novel drug therapies. It is known that in HIV or TB, clinical data 
are predictors of the immune response against pathogens and a successful or unfavorable disease outcome70,71. 
Therefore, we contrasted plasma hormone concentrations with clinical data from patients, with remarkably inter-
esting results obtained for 7-oxo-DHEA. On the one hand, we observed a positive and statistically significant cor-
relation between the levels of this hormone levels and absolute CD4+ T cell count or CD4+ T cell nadir values in 
HIV-TB patients. On the other hand, we discovered that higher concentrations of 7-oxo-DHEA were associated 
with the development of a restricted pulmonar TB instead of disseminated infection.
First, the peripheral CD4+ T cell count is a standard measure of disease progression in HIV-infected individ-
uals, since a higher CD4+ T cell count is associated with a lower short-term risk of AIDS events and higher body 
mass index72,73. Furthermore, HIV+ individuals with fewer peripheral CD4+ T cells are more prone to devel-
oping TB and exhibiting higher viral titers69,74. In the context of TB, it is well established that CD4+ T cells are 
critical for resistance to Mtb, and a functional deficiency of CD4+ T lymphocytes results in impaired granuloma 
formation, leading to failure restricting bacteria replication75,76. Additionally, higher nadir CD4+ T cell counts 
are related with favorable long-term outcomes and specific CD4+ and CD8+ T cell responses in HIV-1-infected 
individuals70,72. Second, clinical manifestations of TB are variable and dependent on a number of characteristics 
Figure 5. 7-oxo-DHEA plasma levels are associated with a favorable clinical outcome. (a) 7-oxo-DHEA plasma 
levels positively correlated with absolute CD4+ T cell count (number of pairs XY = 11) and the CD4+ T cell 
nadir values (number of pairs XY = 9) in HIV-TB patients. Solid lines represent linear regression curves and 
dotted lines symbolize 95% confidence intervals. Spearman’s rank correlation coefficient, p value and slope are 
indicated. (b) HIV-TB patients with pulmonar TB exhibited higher 7-oxo-DHEA concentrations compared to 
those with extrapulmonar TB. Each symbol represents an individual subject (n values are shown). Horizontal 
lines represent mean values and error bars symbolize SEM. Mann-Whitney U test. ** p < 0.01.
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of the host immune system. Before the advent of the HIV pandemic, most of the TB cases reported were limited 
to the lungs, but an increase was later observed in the frequency of extrapulmonar TB in people whose immune 
function was compromised77. The frequency of TB (pulmonar as well as extrapulmonar) in subjects infected with 
HIV rises with the advance of immunosuppression78. In line with this, an epidemiological study has shown that 
people with pulmonar TB present higher CD4+ lymphocyte counts than those with extrapulmonar TB, indicat-
ing an immune system failure in pathogen control78.
To the best of our knowledge, this is the first report showing the simultaneous measurement of DHEA, AED, 
AET and 7-oxo-DHEA in plasma from HIV-TB individuals using HPLC-MS/MS technology. Our findings about 
7-oxo-DHEA suggest that this DHEA metabolite with weak estrogenic and androgenic activities31–33 may be 
involved in the development of an effective immune response against Mtb and/or HIV in co-infected individuals. 
Generally, patients who fail to establish an adequate response against specific pathogens need the use of combined 
traditional and adjuvant therapies, and steroids are among the immunomodulatory compounds most commonly 
used79–81. Therefore, the results originated in this research work encourage us to develop more comprehensive 
studies regarding the role of these hormones in the pathology of HIV-TB co-infection.
Methods
Chemicals. DHEA (Fig. 1) (purity 99%), internal standard (IS) 16-methylene-17α-hydroxypregnenolone 
3-acetate (Fig. 1) (purity 99%), sodium borohydride powder (NaBH4, purity ≥ 98.0%), lithium hydroxide, (LiOH, 
grade 98%), acetic anhydride (Ac2O, purity ≥ 99%), tertbutyl hydroperoxide (TBHP, solution 70% in H2O), 
Cerium (III) chloride heptahydrate (CeCl3, 99.9% trace metals basis), sodium chlorite (NaClO2, technical grade 
80%), sodium sulfate (Na2SO4, ≥ 99.0%, anhydrous, granular), and formic acid (grade ≥ 95%) were purchased 
from Sigma-Aldrich Chemical Co (St. Louis, Missouri, USA). Solvents dichloromethane (CH2Cl2), methanol 
(MeOH), tetrahydrofuran (THF), pyridine (PY), ethyl acetate (EtOAc), hexane (HEX) and acetonitrile (ACN) 
were obtained from SINTORGAN S.A. (Buenos Aires, Argentina). All solvents and reagents were of analytical 
grade, with the exception of those used in HPLC-MS/MS, which were HPLC grade.
Synthesis. All synthetic compounds were purified by column chromatography on silica and their NMR spec-
tra were recorded on a Bruker AM-500 spectrometer (500 MHz for 1H and 125.1 MHz for 13C). The grade of 
purity achieved was > 99%.
AED (Fig. 1) was synthesized from DHEA by a reduction reaction with NaBH4 as previously described82, but 
solvent was modified by CH2Cl2:MeOH (1:4). The reaction was monitored by TLC and completed within 60 min. 
The solvent was evaporated in vacuo and the residue was taken in EtOAc and purified by column chromatography 
(HEX/EtOAc gradient).
7-oxo-DHEA (Fig. 1) was obtained from DHEA through three steps of synthesis. First, 1 equivalent of DHEA 
and 4 equivalents of acetic anhydride were dissolved in pyridine during 20 hours at room temperature to obtain 
3-AcO-DHEA. Then, this compound was oxidized according to Silvestre and Salvador83 using NaClO2 and 
TBHP. Finally, the product was hydrolyzed with KOH in MeOH:H2O (8:2) during 2 hours at room temperature, 
extracted with EtOAc and purified by column chromatography (HEX/EtOAc 1:1).
AET (Fig. 1) was synthetized utilizing previously described conditions of Luche reduction84 from 3-AcO-
7-oxo-DHEA, an intermediate compound in the synthesis of 7-oxo-DHEA. Then, the hydrolysis of 3-AcO group 
was achieved with LiOH. The crude mixture was purified by column chromatography (HEX/EtOAc1:1) to give 
the final product.
Study subjects. In the current study, we recruited 33 subjects (Table 3) which were classified into two 
groups: 1) healthy donors (HD), with no history of TB, HIV or systemic infections; 2) HIV–TB patients, chron-
ically HIV-1+ infected with active TB who received none or less than one week of anti-TB therapy. HIV diagno-
sis was determined by ELISA and confirmatory Western blot, while TB was detected through identification of 
acid-fast bacilli in sputum, a positive culture of TB bacilli and/or radiological data. Some HIV–TB individuals 
were on anti-retroviral treatment following the current guidelines85. None of the subjects had metabolic or endo-
crine disorders or received DHEA or glucocorticoids. Patients were evaluated at Hospital J.A. Fernández, Buenos 
Aires, Argentina. The investigation was approved by the Ethics Committee from Fundación Huésped, Buenos 
Aires, Argentina. Written informed consent was obtained from all participant subjects. In addition, all experi-
ments were performed in accordance with current guidelines and regulations.
Sample preparation. Plasma samples were obtained by centrifugation from peripheral blood collected dur-
ing the morning, stored at −80 °C in plastic tubes and thawed at the time of extraction. One ml of plasma was cen-
trifuged for 3 minutes at 4000 RPM in order to remove residual cells and particulate matter. Afterwards, plasma 
was transferred into a glass tube and the residue was washed with 250 μl of distilled water, it was centrifuged again 
and the supernatant was added to the plasma and spiked with IS (Fig. 1) at a final concentration of 40 ng/ml.
In order to extract unconjugated steroids, plasma samples were mixed with 2 ml of EtOAc, vortexed for 30 sec-
onds and after 10 minutes the organic layer was transferred into another glass tube. This procedure was repeated 
2 more times with 1.5 ml of EtOAc. The pooled organic layer was dried with 300 mg of sodium sulfate, the super-
natant was filtrated and the solvent was evaporated in vacuo. The residue was taken in MeOH and filtrated with 
a syringe filter Millex-LG (0.20 µm, PTFE hydrophilic, 13 mm. Millipore, Darmstadt, Germany). The resulting 
filtrate was collected into an autosampler vial with inserts (MRQ™ Vials w/RSA™ Glass-12 × 32 mm, 1.2 ml) and, 
after removal of the solvent with a nitrogen stream, the extract was dissolved in 100 μl of MeOH before injection 
into the liquid chromatograph. Subsequently, the area acquired for each metabolite was relativized to the area of 
IS in order to calculate the concentration.
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Calibration standard and quality controls (QC). Calibration standards and QC were prepared spiking 
with 10 μl of a stock solution of standards at MeOH in 1 ml of: (1) MeOH (solvent) or (2) a pool of plasma from 
HD (pooled plasma). Curves included seven calibration levels at a final concentration of 3, 10, 30, 100, 300, 1000 
and 3000 ng/ml. We used three replicates for each level of the calibration curves. Additionally, each point was 
spiked at 40 ng/ml of IS and processed as described above. The curves were obtained by plotting the “peak area of 
standard compound/peak area of IS” ratio (response) against the analyte spiked concentration. QC were prepared 
in the same way as calibration standards at 3 ng/ml as the lower limit of quantitation (LLOQ), 10 ng/ml as lower 
QC (LQC) and 3000 ng/ml as higher QC (HQC).
Limit of detection (LOD), limit of quantitation (LOQ), linearity, accuracy, precision (intra and interday), 
recovery and process efficiency were calculated (Table 2). In order to calculate the LOD and LOQ, a solution of 
standards in MeOH was used. Serial dilutions (from 300 to 3 ng/ml) of the standards in MeOH were prepared 
and injected into the mass spectrometer in decreasing order. From the response of each analyte concentration, the 
“signal-to-noise” ratio (S/N) was calculated. LOD was defined as a S/N superior to 3, while LOQ was determined 
as the lowest concentration at which S/N ratio was greater than 1034,86–88.
Precision and accuracy were calculated for LLOQ, LQC and HQC. Accuracy was calculated as the mean rela-
tive error (RE%) of 5 independent determinations in different days, while precision was assessed as the coefficient 
of variation (CV%) of 5 independent determinations during the same day (intraday) or 5 measures on different 
days (interday).
With the intention of studying matrix effect (ME), the recovery (R) and the efficiency of the process (PE), three 
different solutions fortified with standards at 30 ng/ml and IS at 40 ng/ml were prepared: (A) MeOH solution; 
(B) Extracted pooled plasma, spiked prior to HPLC injection; (C) Supplemented pooled plasma, subsequently 
submitted to the extraction procedure. Matrix effect was evaluated in two ways: (1) Contrasting the curve slopes 
of solvent and fortified pooled plasma calibration curves34,89; (2) Comparing the response in triplicate from A with 
B calculated as: ME%: B/A × 100.The relative and absolute extraction recoveries were evaluated comparing in 
triplicate B and C. The calculation of relative recoveries was based on the formula: Relative R (%) = response from 
C/response from B × 100. Absolute recovery was calculated as: Absolute R (%) = analyte area from C/analyte 
area from B × 100. Process efficiency was estimated by multiplying the ME by the R, expressing the ratio of the 
response of an analyte spiked before extraction (C) and the response of the same analyte in a MeOH solution (A)37.
HPLC-MS/MS conditions. An interlaboratory comparison with subject samples was conducted at two lab-
oratories: (1) laboratory of reference, where this approach was developed; (2) secondary laboratory, where the 
results of analyte quantitation were compared by a correlation analysis.
The equipment owned by the laboratory of reference was acquired from Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA). Separation and quantification of steroids was performed using an Ultimate 
3000 RSLC Dionex HPLC coupled with a TSQ Quantum Access Max triple quadrupole mass spectrometer. 
Electrospray ionization (ESI) in positive ion mode with a heated electrospray ionization (HESI-II) probe and 
method of multiple reaction monitoring (MRM) were used for performing mass spectrometric quantitation. 
The conditions were as follows: 25 psi sheath gas (nitrogen), 5 psi auxiliary gas (nitrogen), 1.5 mTorr collision gas 
(argon), 5000 V ion spray voltage and 200 °C vaporizer temperature.
Chromatographic separation was carried out on a Hypersil GOLDC18 1.9 μm (50 × 2.1 mm) column at 25 °C 
with an injection volume of 6 μl. Mobile phase consisted of water (solvent A) and ACN (solvent B), both with 
0.1% formic acid as additive to improve electrospray ionization90. The flow rate was set at 0.20 ml/min. Running 
started with a linear gradient of solvent B from 20% to 30% in 10 minutes, then a plateau until minute 20, a linear 
gradient to 95% for 2 minutes, a 4 minute plateau and finally a gradient to 20% until minute 28, ending with a 
re-equilibration step for 4 minutes. This method allowed separation of all compounds within 32 min. LC sepa-
ration combined with tandem MS spectrometry enabled the differentiation of each compound by their reten-
tion times and MRM transitions (Table 1). Data acquisition was analyzed with Thermo Scientific™ Xcalibur™ 
software.
The cross-validation assay was performed in a secondary laboratory with equipment purchased from Agilent 
Technologies (Santa Clara, CA, USA). UHPLC analysis was performed on a 1290 Infinity II LC with a ZORBAX 
Rapid Resolution High Definition SB-C18 2.1 × 50 mm (1.8 μm) column at 25 °C and an injection volume of 5 μl. 
Flow rate was set at 0.220 ml/min and the elution gradient was optimized for this equipment, using the same 
mobile phase. Running began with a linear gradient from 20% to 40% solvent B in 6 minutes, then a plateau of 
4 minutes, a linear gradient to 95% solvent B until minute 12 followed by a 5-minute plateau, another gradient 
to 20% B for 2 minutes and a re-equilibration step to the initial conditions for 2 minutes. This optimized method 
allowed the separation of compounds within 20 min. Quantification was carried out in an Agilent 6460 Triple 
Quadrupole LC/MS with Standard ESI Source under the same conditions specified above (Table 1) and analyzed 
with MassHunter Workstation software.
Statistics. Statistical analyses were conducted using GraphPad Prism 6 software. Matrix effects were evalu-
ated by comparing solvent and matrix calibration curves by the standard-addition method34,89. The comparison 
of measurements by LC-MS/MS with radioimmunoassay (RIA, Packard Cobra II Gamma Counter, Packard, 
Meriden, CT, USA)12, as well as the interlaboratory study, were analyzed through Spearman’s rank correlation 
coefficient. Comparisons between groups (HD and HIV-TB) were performed using the non-parametric Mann–
Whitney U test. For all evaluations, a p value < 0.05 was considered significant.
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